Sanofi India Promoter Group Announces 15.20% Inter-Se Share Transfer

Shares Proposed for Transfer: Up to 3,500,000 equity shares (15.20%)

Reference VWAP: ₹3,228.06 per share (60-trading-day VWAP)

Reader Takeaway: Promoter restructuring only; no change in overall promoter control or public shareholding.

What just happened

Sanofi Healthcare India Private Limited has informed the stock exchanges of its intention to acquire up to 35 lakh equity shares of Sanofi India Limited from Hoechst GmbH.

The proposed acquisition represents 15.20% of the company's paid-up equity share capital and is scheduled to take place on or after September 24, 2026.

The filing states that the transaction is an inter-se transfer between promoter group entities.

Why this matters

The proposed acquisition is an internal promoter restructuring and does not represent an acquisition from public shareholders.

Under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the transaction qualifies for exemption from the mandatory open offer requirement under Regulation 10(1)(a)(iii).

What changes now

Following completion of the transaction:

• Sanofi Healthcare India Private Limited's holding will increase from zero to 35,00,000 equity shares, equivalent to 15.20%.
• Hoechst GmbH's shareholding will decline from 60.38% to 45.18%.

The filing makes it clear that the transfer is between promoter entities and does not result in any change in control of Sanofi India Limited.

Risks to watch

There are no operational or business changes announced in this disclosure.

Investors should monitor completion of the proposed transfer and any subsequent promoter shareholding disclosures filed with the exchanges.

What to track next

The next update will be confirmation that the inter-se transfer has been completed along with the revised promoter shareholding pattern in future regulatory filings.